Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06868836
What this trial is testing

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 78
Early research (Phase 1)Study completedNCT06181786
What this trial is testing

Study of NAV-240 in Healthy Volunteers

Who this might be right for
Healthy
Navigator Medicines, Inc. 40
Testing effectiveness (Phase 2)UnknownNCT05522894
What this trial is testing

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Who this might be right for
Unresectable Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell Carcinoma
Chinese Academy of Medical Sciences 80
Early research (Phase 1)Study completedNCT05821231
What this trial is testing

Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma

Who this might be right for
Soft Tissue Sarcoma
Institut Claudius Regaud 14
Testing effectiveness (Phase 2)Study completedNCT00204594
What this trial is testing

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

Who this might be right for
Malignant Melanoma
University Hospital Tuebingen 1
Early research (Phase 1)Looking for participantsNCT05646550
What this trial is testing

Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer

Who this might be right for
Prostate Cancer Recurrent
University Hospital Tuebingen 56
Testing effectiveness (Phase 2)Looking for participantsNCT06975410
What this trial is testing

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Who this might be right for
EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
Yuhan Corporation 80
Early research (Phase 1)Looking for participantsNCT07195916
What this trial is testing

Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Solid TumorsHematologic Malignancies
Incyte Corporation 280
Early research (Phase 1)Looking for participantsNCT07093554
What this trial is testing

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Medical College of Wisconsin 31
Early research (Phase 1)UnknownNCT05780307
What this trial is testing

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerSmall Cell Lung Cancer+3 more
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07064902
What this trial is testing

Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University 48
Early research (Phase 1)Study completedNCT02766699
What this trial is testing

Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Who this might be right for
GlioblastomaAstrocytoma, Grade IV
Engeneic Pty Limited 9
Early research (Phase 1)Study completedNCT00911898
What this trial is testing

MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Who this might be right for
Her2 Amplified Solid TumorsMetastatic Breast Cancer
Merrimack Pharmaceuticals 20
Testing effectiveness (Phase 2)UnknownNCT05430906
What this trial is testing

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hunan Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06841055
What this trial is testing

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 60
Testing effectiveness (Phase 2)Looking for participantsNCT03526835
What this trial is testing

Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced/Metastatic Solid TumorsColorectal CancerGastric Cancer+5 more
Merus B.V. 560
Testing effectiveness (Phase 2)UnknownNCT05176665
What this trial is testing

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Who this might be right for
NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
Shanghai EpimAb Biotherapeutics Co., Ltd. 152
Early research (Phase 1)Study completedNCT03922204
What this trial is testing

Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Who this might be right for
Advanced CancerSolid Tumor, AdultB-cell Lymphoma, Adult
Merus B.V. 72
Testing effectiveness (Phase 2)UnknownNCT06424821
What this trial is testing

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Who this might be right for
NSCLC
Shanghai Pulmonary Hospital, Shanghai, China 54
Early research (Phase 1)Study completedNCT05116007
What this trial is testing

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Who this might be right for
SCLC, Extensive Stage
Akeso 35
Next Page